Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1258225 | 1.00 | ALDH1A1 (0.40) | ALDH1A1LMNAKDM4ELPAR1LPAR5 | |
| SCHEMBL1260165 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL1260162 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL1259102 | 0.84 | KDM4E (0.39) | ALDH1A1LMNAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL1259107 | 0.84 | KDM4E (0.39) | ALDH1A1LMNAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL1259043 | 0.84 | CDK8 (0.41) | LPAR1LPAR5PDK1 | |
| SCHEMBL12892590 | 0.76 | MAPT (0.44) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1259639 | 0.76 | SLC22A12 (0.47) | LMNAKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL29569131 | 0.75 | HSPB1 (0.63) | ALDH1A1LMNAHTTHSPB1 | |
| SCHEMBL4480985 | 0.74 | MAPT (0.50) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| WO-2009136663-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | ALDH1A1 2255/4885LMNA 3734/4885KDM4E 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.